Lenalidomide prolonged-release formulation NEX-20A

{
  "id": "MLC-T-ONC-014738",
  "term": "Lenalidomide prolonged-release formulation NEX-20A",
  "field": "Oncology and biomedicine",
  "definition": "A prolonged-release formulation composed of a suspension of the thalidomide analog lenalidomide coated with slow-dissolving nontoxic inorganic oxides, with potential antineoplastic activity. Upon administration via subcutaneous injection, the coating dissolves and lenalidomide is released. Lenalidomide inhibits tumor necrosis factor alpha (TNF-alpha) production, stimulates T lymphocytes, reduces serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibits angiogenesis. Additionally, lenalidomide promotes G1 cell cycle arrest and induces apoptosis in malignant cells.",
  "synonyms": [
    "lenalidomide long-acting formulation NEX-20A"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lenalidomide-prolonged-release-formulation-nex-20a/"
}